ADMINISTRATIVE SUPPLEMENTS TO SHARE RESEARCH RESOURCES FOR GENETIC STUDIES ON AUTISM RELEASE DATE: June 30, 2003 NOTICE: NOT-MH-03-006 National Institute of Mental Health (NIMH) (http://www.nimh.nih.gov/) National Institute of Neurological Disorders and Stroke (NINDS) (http://www.ninds.nih.gov/) National Institute on Deafness and Other Communication Disorders (NIDCD) (http://www.nidcd.nih.gov/) National Institute of Child Health and Human Development (NICHD) (http://www.nichd.nih.gov/) RECEIPT DATE: September 1, 2003 PURPOSE The National Institute of Mental Health (NIMH), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Deafness and Other Communication Disorders (NIDCD), and the National Institute of Child Health and Human Development (NICHD) announce an administrative supplement program for currently funded NIH research projects, in order to encourage the collection and timely sharing of research resources for genetic studies on autism through the NIMH Center for Genetic Studies ("the Center") (http://zork.wustl.edu/nimh/). The Center allows receipt, storage, maintenance, standardization, quality control, and equitable, ethical distribution to the broader scientific community of DNA, clinical information, genotyping data and other resources important for genetic studies of autism. It is NIH's intent to include in this program all eligible research groups worldwide who have collected data that could be utilized in genetic research on autism. RESEARCH OBJECTIVES Background The sharing of data is critical for the rapid progress of research investigating the genetic basis of human disease. It is particularly important for disorders like autism and other mental disorders that are genetically complex and clinically heterogeneous. For such disorders, large sample sizes are often essential for achieving adequate statistical power for genetic analysis. Other scientific advantages of sharing data and research resources include: facilitating the rapid replication of new findings, stimulating multidisciplinary research among clinical and basic scientists, providing needed clinical resources to promising young investigators, clarifying discrepancies in results obtained from multiple data sets, avoiding duplicative data collection efforts and laboratory work, and facilitating the rapid application of state-of-the-art genomic technologies and analytic methods to clinical data sets. This administrative supplement program is open to all researchers who are working on an ongoing NIH project in which autism samples have already been collected. Funds will be provided to support the collection of blood and data and related activities necessary for future genetic studies. This effort ultimately will facilitate genetic research on autism and related disorders by the broader scientific community. Cell lines, DNA, diagnostic information, and other clinical data from subjects targeted under this program will be included in the NIMH Human Genetics Initiative (http://zork.wustl.edu/nimh/NIMH_initiative/NIMH_initiative_link.html) and will be widely distributed to the scientific community. Successful applications will focus on previously ascertained pedigrees containing multiple affected individuals that were collected for a family-genetic or linkage study in an outbred population, or a linkage disequilibrium mapping study in a genetically isolated population. This includes small nuclear families (affected individuals and their parents). Applications may also include a large sample of well-characterized unrelated affected subjects for inclusion in future case-control association studies. If such an application were to be funded under this program, the supplement will exclusively support collection of cases and will not support collection of control subjects. Areas of Supplemental Support The supplement will provide funds to defray the added costs of collecting blood for submission to the Center, and other related activities (see below). Costs associated with the actual clinical research project are not part of this supplement program. Funds will not be used to support the ascertainment of new pedigrees or of new samples of affected subjects for clinical studies. There will be an anticipated maximum award for 1 year of $200,000 (DIRECT COSTS) per data collection effort. Some NIH research projects may include multiple data collection efforts by different investigators supported under subcontracts or other mechanisms ("clinical sites"), as part of the funded NIH project. Each clinical site may request up to $200,000 (direct costs); in such cases, the aggregate requested direct costs for the NIH research project likely would exceed $200,000. Some clinical sites supported in part or wholly under NIH grant awards to domestic institutions may have collected autism samples in countries other than the United States. Inclusion of these clinical sites in applications to this program is strongly encouraged. Before an award can be made under this supplement program to support the activities of such a clinical site, NIH will require written assurance that shipments of blood and data from the country in question to the Center will be in strict accordance with that country's existing laws and regulations. Funding under this program is contingent on approval of written documentation by an appropriate government official. This program will provide funds to support the following activities, which will become conditions of the award: o Contact or re-contact of autistic probands and relatives in pedigrees (including small nuclear families) currently being studied or followed as part of an NIH-funded research project, regardless of whether NIH supported the initial pedigree ascertainment. o Contact or re-contact of unrelated autistic subjects currently being studied or followed as part of an NIH-funded research project, regardless of whether NIH supported the initial subject ascertainment. o Re-consent of affected individuals and relatives with a consent form template, utilized in the NIMH Human Genetics Initiative and developed with input from the National Human Genome Research Institute's Ethical, Legal, and Social Implications Research Program and the Department of Health and Human Services' Office for Human Research Protection, that explicitly discloses participation in genetic research and acknowledges data sharing and maintenance of DNA and data as national resources for studying the genetic basis of autism. This template is available at (http://zork.wustl.edu/nimh/NIMH_initiative/NIMH_initiative_link.html). Funds provided under this program may be used to support activities (such as personnel time) required of project staff when working with their local institution, including the local Institutional Review Board, to obtain approval of the consent form and to implement it in the project protocol. o The drawing of viable blood samples and submission of these samples to the Center, which will create high-quality lymphoblastoid cell lines to establish an infinitely renewable source of DNA for subsequent genetic analyses. Successful applicants shall ship blood samples in accordance with a blood shipment protocol available from the Center (http://zork.wustl.edu/nimh/NIMH_initiative/NIMH_initiative_link.html) so as to minimize trauma, i.e., excessive heating or freezing. Funds provided under this program may be used to support activities (such as personnel time) needed to ensure that blood drawing procedures meet Center requirements for submission. Also, funds may be used to recover all phlebotomy costs. All samples submitted must be accompanied by required clinical and diagnostic data (see below). o Electronic transfer at regular intervals of clinical, diagnostic, family structure and other data to the Center, on all subjects for whom a blood sample is submitted. Funds provided under this program may be used to support activities (such as personnel time) needed to ensure that data are transmitted in an expeditious fashion to the Center. o Implementation of adequate quality assurance/quality control procedures to ensure high quality of all data provided to the Center. Funds provided under this program may be used to support activities (such as personnel time) needed to ensure that high-quality data are transmitted to the Center. The amount of award will be based on the number of subjects for whom both blood samples and data are submitted to the Center. An initial award will be made to cover the anticipated costs over 3 months of collecting and submitting data and blood samples on the number of "sample units" (see below) anticipated during this period, based on the proposed data collection milestones specified in the application. Funds will then be released at subsequent 3-month intervals based on the number of samples units proposed in the next 3-month period and the success rate realized in the preceding 3-month period. It typically is not feasible for all samples from a sample unit to be submitted to the Center at a single time; therefore, single submissions will be accepted by the Center and tracked until the minimum number required to complete the unit is met. There are four types of possible sample unit submissions: o Affected sib pairs. Two or more affected full siblings from the same family with a diagnosis of autism (not an autism spectrum disorder) constitute a sample unit in this context. This type of sample will be reimbursed at a rate per affected (concordant) sib pair stipulated by the PI in the application. If only these samples units are targeted, a minimum of 10 affected sib pairs is required per clinical site, with a minimum of 20 affected sib pairs in aggregate per research project. Samples submitted in addition to the required minimum number are strongly encouraged. Incurred costs will only be justified for reimbursement per sib pair when data and blood samples from both members of the pair are provided to the Center. o Extended pedigrees. Multigenerational, extended pedigrees that contain at least four affected individuals (at least two of which are diagnosed with autism and not an autism spectrum disorder) constitute a sample unit in this context. This type of sample will be reimbursed at a rate per extended pedigree stipulated by the PI in the application. If only these sample units are targeted, a minimum of two extended pedigrees is required per clinical site, with a minimum of four extended pedigrees in aggregate per research project. Samples submitted in addition to the required minimum number are strongly encouraged. Incurred costs will only be justified for reimbursement per extended pedigree after data and blood samples from all pedigree members are provided to the Center. o Affected individuals and their two parents (trios). For such sample units, only subjects diagnosed with autism (and not an autism spectrum disorder) are to be included. Each sample unit of this type will be reimbursed at a rate per trio stipulated by the PI in the application. If only these samples units are targeted, a minimum of 10 trios is required per clinical site, with a minimum of 20 trios in aggregate per research project. Samples submitted in addition to the required minimum number are strongly encouraged. Incurred costs will only be justified for reimbursement per trio when data and blood samples from all members of the trio are provided to the Center. o Unrelated affected individuals. For such sample units, only subjects diagnosed with autism (and not an autism spectrum disorder) are to be included. Applications may be submitted for funding under this supplement program that propose a large collection of at least 200 unrelated affected individuals for use in future case-control association studies. Such applications will be assigned a lower funding priority than applications that specify pedigree data collection. Each sample unit of this type will be reimbursed at a rate stipulated by the PI in the application per affected subject. A minimum of 100 affected subjects is required per clinical site, with a minimum of 200 affected subjects in aggregate per research project. Samples submitted in addition to the required minimum number are strongly encouraged. Incurred costs per affected individual will only be justified for reimbursement when data and blood samples from the subject are provided to the Center. Collections from a single investigator may include one or a combination of several sample unit types. In applications where there is a mixture of sample units, minimum sample units as stated above need not be met for the purpose of establishing milestones for data collection or reimbursement, but the aggregate must exceed a given threshold. Please contact the NIH staff listed under INQUIRES to discuss the threshold, given the sample unit mixture proposed for collection. The following types of sample submissions will NOT be accepted by the Center: o Existing pedigrees currently included in the NIMH Human Genetics Initiative. o Pedigrees or affected subjects included in the NIH Studies to Advance Autism Research and Treatment (STAART) Centers Program. o Samples other than whole blood (such as brain tissue, buccal swabs or cerebrospinal fluid). o Samples without accompanying clinical and diagnostic data. Applications submitted for funding under this program need to include a detailed description of each of the following, which will be incorporated in the terms and conditions of award (after negotiation with the applicant when necessary): o Targeted number and type of sample units from which data and blood samples will be submitted to the Center, as well as a timeline for submission. o Rates of reimbursement per affected sib pair, extended pedigree, trio, and affected individual (case-control sample). o Structured diagnostic criteria to establish a final best estimate lifetime diagnosis. PIs are expected to employ state-of-the-art methods to synthesize information collected from multiple sources, e.g., a structured diagnostic interview, standardized intelligence testing, medical records, and multiple family informants. o Comprehensive clinical characterization through use of a standardized intelligence test and a highly reliable diagnostic instrument, e.g., Autism Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule Generic (ADOS-G). o A highly operable computerized database of diagnostic and clinical information, which will permit rapid electronic uploads to the Center. This should include a description of the time intervals at which data will be electronically transmitted to the Center. This is not the same as the timeline for release of these data to the wider scientific community, which is specified in the data sharing plan (see below). o A data sharing plan that permits broad sharing of clinical, diagnostic, pedigree structure and other information, according to a specific distribution timeline. The plan is expected to stipulate acceptance of existing NIMH mechanisms and policies for data release, as already established in the NIMH Human Genetics Initiative. [Note: NIMH policies and mechanisms do not specify a specific distribution timeline.] These mechanisms allow for wide distribution by the Center of all information (e.g., demographic, diagnostic, clinical, genotypic, family structure data) and biomaterials (cell lines, DNA samples) to qualified investigators in the scientific community. These mechanisms further specify that NIMH determines to whom and in what format such data and biomaterials are distributed. o Adequate informed consent procedures. The consent form template described above is expected to be utilized, in which the following are addressed: (1) disclosure that biomaterials (DNA, cell lines) and clinical data will be stored at the Center, as part of a national resource of data and biomaterials distributed by NIMH for the genetic analysis of the disease under investigation; (2) assurance that such data will be provided to the Center without personal identifiers; (3) disclosure that analyses of these data will be conducted by other scientists currently not included within the current research team; and (4) disclosure that there is no plan to provide subjects with any financial benefits from commercial products derived from the data. All samples must be collected under an IRB-approved protocol. IRB approval must be documented, and a copy of the IRB approved consent form to be utilized must be submitted prior to funding. Funding under this program is contingent on NIMH approval of consent forms. The Center is not a covered health-care entity according to HIPAA guidelines, but if it were, it would be fully HIPAA-compliant. Applicants should consider applying for a certificate of confidentiality for sample collection done under this supplement. o A request for a specific quantity of DNA or cell lines, to be used for research conducted under the aegis of the PI's NIH research project. NIMH will provide these biomaterials to the PIs at no cost, as a benefit of participation in this administrative supplement program. Prior to shipment, the PI will complete and execute a distribution agreement, available at (http://zork.wustl.edu/nimh/NIMH_initiative/NIMH_initiative_link.html). FUNDS AVAILABLE The NIH institutes named on the notice plan to collectively commit $2.25 million in FY 2003 to fund applications for supplements to existing NIH- supported grants in response to this Notice. Direct costs will be awarded in modules of $25,000, less any overlap and other administrative adjustments. Because the nature and scope of the data collection efforts may vary, it is anticipated that the size of each award will also vary. There will be an anticipated maximum award for 1 year (DIRECT COSTS) of $200,000 for any of the above mechanisms per clinical site. Some NIH research projects may include multiple clinical sites overseen by different investigators supported under subcontracts or other mechanisms as part of the funded activities. In such cases, each clinical site may request a direct cost award of up to $200,000; in such cases, the aggregate requested direct costs for the NIH research project likely would exceed $200,000. For such applications, please contact NIH program staff listed below under INQUIRIES. Although the financial plans of the NIH provide support for this program, supplements awarded as a result of this Notice are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. ELIGIBILITY Those eligible to apply are NIH Principal Investigators (PIs) with a clinical study in which autism subjects were recruited under any of the following mechanisms: Research Project (R01), Education Project (R25), Program Project (P01), Research Program (Cooperative Agreement) (U19), Specialized Center (P50), Research Project (Cooperative Agreement) (U01), Cooperative Clinical Research (Cooperative Agreement) (U10) Specialized Center (Cooperative Agreement) (U54), Research Scientist Development Award Research & Training (K01), Clinical Investigator Award (K08), or Mentored Patient-Oriented Research Career Development Award (K23) grants. To be eligible, projects must be ongoing at the start of the supplement start date (studies ongoing under a no-cost extension are eligible). REQUIREMENTS FOR SHARING RESEARCH RESOURCES The sharing of clinical data and biomaterials in a timely manner is an important element in progress toward understanding the neurobiological basis of autism. This administrative supplement program is responsive to the NIH Grants Policy Statement requiring investigators to provide prompt and effective access to unique research resources generated by NIH funds (http://grants.nih.gov/grants/policy/nihgps_2001/part_iia_6.htm - _Toc504811860). As described above, applications must include a data sharing plan. Data and biomaterials from subjects included in projects funded by these administrative supplements will be made available and distributed through the NIMH Human Genetics Initiative to the broader scientific community. HUMAN SUBJECTS All applicable regulations that govern human subjects protection from research risk must be addressed. The definition of human subjects in Title 45 CFR Part 46, the Department of Health and Human Services regulations for the protection of human subjects applies, i.e., "Human subject means a living individual about whom an investigator (whether professional or student) conducting research obtains (1) data through intervention or interaction with the individual, or (2) identifiable private information." These regulations specifically address the protection of human subjects from research risks. It should be noted that there are research areas (Exemptions 1-6) that are exempt from these regulations. However, under these guidelines, NIH-supported biomedical and behavioral research projects involving human subjects, whether of not exempt from the human subjects regulations must still address the inclusion of women and minorities in their study design (http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm, and children http://grants.nih.gov/grants/guide/notice-files/not98-024.html). Thus, all biomedical and behavioral research projects involving human subjects will be evaluated for compliance with this policy. Research involving the collection or study of existing data, documents, records, pathological specimens, diagnostic specimens, or tissues that are individually identifiable also is included within the term "research involving human subjects." APPLICATION PROCEDURES 1) Fill out a face page, including appropriate signatures, from Grant Application Form PHS 398 (Revised May, 2001), found at (http://grants.nih.gov/grants/funding/phs398/phs398.html .) Include the title and grant number of the parent grant on line 1 and enter Notice MH-03-006, "Administrative Supplements To Share Research Resources For Genetic Studies On Autism" on line 2. 2) Prepare a project description (6-page limit), including the following: o Performance site(s) o Key personnel o Targeted sample o Targeted number of affected sib pairs, extended pedigrees, trios, and affected subjects (if a case-control sample unit is included) for whom a blood sample and data will be submitted to the Center o Data collection timeline o Structured diagnostic criteria o Phenotypic assessments, e.g., ADOS-G o Information regarding the computerized database o Data quality assurance/quality control procedures o Which data will be electronically transmitted to the Center, and at what time interval o Request for specific quantity of DNA per subject and/or cell lines o Data sharing plan o Rates of reimbursement per affected sib pair, extended pedigree, trio, and affected individual (case-control sample) 3) The abstract and specific aims of the parent grant (2-page limit). 4) An itemized proposed budget and budget justification entered on the budget pages from Grant Application Form PHS 398. Supplements should be requested in modules of $25,000 in DIRECT COSTS, up to a maximum of $200,000 per clinical site. Projects with multiple independent clinical sites may request an aggregate direct cost budget for the NIH research project that exceeds $200,000. 5) Letters indicating approval and commitment of resources from collaborating institutions. 6) IRB approval of a consent form containing key elements described above related to data sharing, or agreement to obtain such approval prior to funding. 7) Written agreement to electronically submit to the Center data on all subjects for whom a blood sample is sent to the Center. 8) Written agreement to ship blood samples in accordance with existing Center protocols. 9) Written acceptance of existing NIMH mechanisms and policies for data release, as already established in the NIMH Human Genetics Initiative. 10) Written assurance for foreign clinical sites that shipments of blood and data from the country in question to the Center are in strict accordance with that country's existing laws and regulations, or agreement that such written assurance will be obtained prior to funding. 11) The original and two copies of the entire application package must be sent directly to Dr. Steven Moldin at the address listed under INQUIRIES. 12) Applications must be received by September 1, 2003. 13) The supplemental award will be made prior to September 30, 2003, after favorable evaluation and approval by NIH staff. ADMINISTRATIVE REVIEW CONSIDERATIONS Applications for submission will be evaluated administratively by NIH staff. All funding decisions are final and are not subject to appeal. Applicants should provide the following information for consideration in the administrative review: o How the proposed activities will be incorporated into the parent project; o Size of available pedigree or case-control sample; o Number and diagnoses of expected sample units (affected sib pairs, extended pedigrees, trios, affected individuals for a case-control sample) and total number of affected and unaffected subjects for which a blood sample and data are to be provided to the Center; o Feasibility of obtaining targeted number of sample units; o Quality of diagnostic and other clinical assessments; o Open operability of the computerized database, to permit electronic transmission of data to the Center; o Data quality assurance/quality control procedures; o Rate of reimbursement per affected sib pair, extended pedigree, trio, and affected individual (case-control sample). INQUIRIES Inquiries concerning this Notice are encouraged. The opportunity to clarify any issues or answer questions from potential applicants is welcome. o Direct inquiries regarding programmatic issues to: Steven O. Moldin, Ph.D. Office of Human Genetics and Genomic Resources Division of Neuroscience and Basic Behavioral Science National Institute of Mental Health 6001 Executive Boulevard, Room 7189, MSC 9643 Bethesda, MD 20892-9643 Telephone: (301) 443-2037 FAX: (301) 443-9890 Email: smoldin@mail.nih.gov o Direct inquiries regarding fiscal matters to: Carol J. Robinson Grants Management Branch National Institute of Mental Health 6001 Executive Boulevard, Room 6118, MSC 9605 Bethesda, MD 20892-9605 Telephone: (301) 443-3858 FAX: (301) 443-6885 Email: crobinso@mail.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.